The intravenous drug can be used as a short-term replacement therapy for patients with certain types of seizure disorders when oral administration of the drug is not possible.
San Diego, Calif.-based Ligand Pharmaceuticals, a partner of Lundbeck, will earn a $1.25 million milestone payment for the approval and is entitled to 2.75 percent of Carnexiv’s net sales.
Lundbeck plans to launch Carnexiv in early 2017.
More articles on supply chain:
Southwest Airlines to haul international cargo next year
Dana-Farber, Brigham and Women’s in ‘urgent need’ of platelet donations
Southwest Airlines to haul international cargo next year
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
